We are providing access to selpercatinib for adults with locally advanced or metastatic solid tumors that have specific genetic changes. This program aims to help patients who may benefit from this targeted treatment.
We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.
We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.
We are testing a new cell therapy to see if it helps patients with acute respiratory distress syndrome caused by viruses like COVID-19 and influenza. The study will evaluate its safety and effectiveness in reducing severe immune responses.
We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.
We are studying a new skin graft for patients with deep partial and full-thickness burns to see if it helps wounds heal and reduces scarring better than standard treatments. This trial aims to improve recovery outcomes for burn patients.
We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.
We are evaluating a new treatment for adults with Frontotemporal Dementia linked to GRN or C9orf72 mutations. The study aims to understand its safety and how well it works in this specific group.
We are studying a new treatment using Glofitamab after Obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Our goal is to evaluate its safety and effectiveness compared to standard treatments.
We are testing a new nasal treatment to see if it is safe and effective for patients. This study also explores how it affects the nasal microbiome.
We are investigating how naldemedine affects bowel function in individuals using opioids like tramadol. The goal is to see if it improves gastrointestinal movement and overall bowel health.
We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.
We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.
We are studying whether progesterone can help reduce the risk of preterm birth in women diagnosed with placenta previa. This trial will look at various outcomes, including the timing of birth and any side effects for mothers and babies.
We are studying the effects of removing part or all of the pancreas and transplanting the patient's own islet cells in patients with pancreatic cancer at high risk for complications. The goal is to see if this approach improves safety and quality of life.
We are evaluating the safety of MAQ-001, both alone and with other treatments, for patients with advanced cancers. This study aims to understand how well it works in this patient group.
We are studying a new treatment combination for patients with KRAS G12C-mutant metastatic lung cancer. The goal is to see if it works better than standard treatment in improving survival and quality of life.
We are studying a combination of two treatments before and after surgery for patients with early-stage non-small cell lung cancer. The goal is to see if this approach improves tumor response and safety compared to standard treatments.
We are studying whether the medication bosentan can help reduce coronary artery spasms in patients with ongoing angina symptoms. The trial also aims to evaluate its effects on quality of life and safety.
We are testing a new treatment called TAK-755 for patients with immune-mediated thrombotic thrombocytopenic purpura. The study aims to see if it is safe and effective in reducing symptoms and preventing future episodes.